Janet K. Yamamoto
Department of Infectious Diseases and Pathology
PO Box 110880
2015 SW 16th Ave
Gainesville, FL 32608-0880
FAX: (352) 392-9704
PhD, Microbiology (Immunology), The University of Texas Medical Branch, Galveston, 1981
Honors and Awards
- University of Florida Research Foundation Professorshoip Award, 2011
- Faculty Achievement Recognition, University of Florida, 2007
- Ad hoc grant reviewer, Medical Research Council, UK, 2006
- Regular member, AIDS Immunology & Pathogenesis Study Section, NIH, NIAID, 2005-present
- Pfizer Animal Health Award for Research Excellence, University of Florida, 2005
- Ad hoc grant reviewer, Medical Research Council, UK, 2003, 2004
- Honorary member, Upsilon Chapter of the Society of Phi Zeta, 2002
- University of Florida Research Foundation Professorshoip Award, 2002
- Ad hoc member, Study Section on AIDS K08, NIH, 2002
- International Advisory Committee, Intl. Feline Retrovirus Research Symposium, 2000-present
- Ad hoc member, AIDS ARR 2 Study Section, NIH, 2000, 2004
- Ad hoc member, Vaccine Special Emphasis Panel (VACC 01, 02, 03, 010), NIH, 1998-2005
- Ad hoc member, Study Section on Small Business and STTR Grants, NIH, NIMH, 1998
- Ad hoc team leader, Primate Research Center Site Visit, NIH, NCRR, 1998
- Pfizer Animal Health Award for Research Excellence, University of Florida, 1996
- Ad hoc member, Primate Research Center Site Visit, NIH, NCRR, 1996
- Ad hoc member, Minority Enhancement Program Study Section, NIH, NIAID, 1995
- Ad hoc member, Panel on RFA on Blood Brain Barrier in HIV, NIH, NIMH, 1995
- Regular member, AIDS & Immunology Study Section (MHAI2), NIH, NIHM, 1994-1998
- Member, Immunology & Microbiology Study Section, American Heart Assoc., 1993-1995
Our major research interests are to identify cellular immune functions that are essential for T-cell based vaccines, to develop immunotherapeutic drugs for infectious diseases and cancers, and to design computational models for major histocompatibility complex (MHC)-related diseases and therapeutics. Our laboratory has successfully produced semi-inbred cats to evaluate the role that MHC plays in vaccine prophylaxis and immunotherapeutics. Due to close homology between human and feline MHC, the semi-inbred cats are not only useful for veterinary medicine but serve as an excellent small animal model for designing human vaccines and immunotherapeutics. Adoptive-transfer studies with semi-inbred mice are being used to identify the immune cell types and viral epitopes essential for prophylactic protection against emerging and re-emerging viruses (e.g., immunodeficiency viruses, influenza viruses) of humans and cats. Using information derived from these studies, databases are being developed for viral peptides and feline MHC binding pockets in context to the results from efficacy trials. Such databases are the foundation for designing computational models needed to expedite the development of T-cell based vaccines as well as T-helper based antibody vaccines. Furthermore, vaccine approaches based on T-cell immunity when combined with biological mediators can be used as nonprophylactic therapeutics against viral diseases and cancers.
Abbott JR, Pu R, Coleman JK, Yamamoto JK: Utilization of feline ELISPOT for mapping vaccine epitopes. Methods Mol Biol. 2012;792:47-63.
Abbott JR, Sanou MP, Coleman JK, Yamamoto JK: Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine. Vet Immunol Immunopathol. 2011 Oct 15;143(3-4):246-54. Epub 2011 Jun 12.
Yamamoto JK, Sanou MP, Abbott JR, Coleman JK: Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res. 2010 Jan;8(1):14-25. Review.
Yamamoto, JK, Pu R, Sato E, Hohdatsu T: FIV pathogenesis and development of a dual-subtype FIV vaccine. AIDS. 21:547-563, 2007
Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK: HIV-1 p24 vaccine protects cats against FIV. AIDS. 19:1457-1466, 2005.
Additional publications here.